New round of financing for Cellomics, led by its initial seed investor Carl Zeiss Jena
Finance secured New round of financing for Cellomics, led by its initial seed investor Carl Zeiss Jena.
Cellomics has announced a $15m round of financing led by Carl Zeiss Jena.
Zeiss was the initial seed investor in Cellomics.
Other investors include Oxford Bioscience Partners, InterWest Partners, Vector Fund, Alta Partners, and Axiom Ventures.
Cellomics collaborated with Zeiss in 2000 to design, engineer and manufacture the KineticScan HCS reader and KineticScan HCS workstation to perform high content screening (HCS) for drug discovery, basic biomedical research and specialty testing.
Zeiss also supplies the optical sub-assembly for the ArrayScan HCS reader.
"We are very pleased to have Zeiss take the lead in this financing and appreciate the continued commitment they have made to Cellomics," stated Lansing Taylor, president and CEO, Cellomics.
"Our relationship with Zeiss, beginning with the early stages of the company, has always been beneficial to the organisation and the advancement of high content screening.
HCS will continually evolve in sophistication and our strengths in application biology and software, reagents and informatics are complemented by the optical engineering and manufacturing strengths of Zeiss."
